Protein histidyl modification to diphthamide

Across TCGA cell cohorts, RNA activity of the Protein histidyl modification to diphthamide pathway is significantly associated with the drug response of multiple features, with the BLOOD_Myeloma cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Olaparib, TWS119, and Cediranib, each associated with the pathway in up to 3 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Olaparib grouped by Protein histidyl modification to diphthamide-low versus -high activity in BLOOD_Myeloma.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Myeloma	Olaparib →	+0.486	+0.456	.002	.046	3	3
LUNG_SCLC	TWS119 →	+1.284	+0.852	.020	.026	3	3
BLOOD_Leukemia	Cediranib →	+0.171	+0.223	.011	.033	3	3
BLOOD_Leukemia	Tipifarnib →	-0.846	-0.198	.018	.020	3	3
BLOOD_Leukemia	KIN001-244 →	-1.025	-0.292	.020	.013	3	3
BLOOD_Leukemia	PHA-793887 →	-1.247	-0.322	.011	.024	3	3

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Olaparib by Protein histidyl modification to diphthamide activity — BLOOD_Myeloma

Explore this box plot interactively →